摘要
目的观察长春瑞滨联合奈达铂治疗晚期头颈部恶性肿瘤临床疗效与安全性。方法对72例晚期头颈部癌患者给予奈达铂80mg／m^2，d。；长春瑞滨25mg／m^2，d1、dg。每21天为1个周期，至少应用2个周期。结果完全缓解（CR）3例，部分缓解（PR）37例，稳定（SD）18例，进展（PD）14例，近期客观有效率（RR）为55．6％（40／72），其中初治病例有效率为72．2％（13／18），复治病例有效率为50．0％（27／54）。常见的毒性反应是骨髓抑制和消化道反应，骨髓抑制主要表现为白细胞与血小板减少，发生率分别为62．5％（45／72），48．6％（35／72），Ⅲ-Ⅳ度发生率仅为8．3％、11．1％，消化道反应主要表现为轻度的恶心、呕吐，未见明显的肝肾功能异常。结论长春瑞滨联合奈达铂治疗晚期头颈部恶性肿瘤有较好的疗效．并且毒性反应可以耐受。值得临床推广使用。
Objective To evaluate the efficacy and toxicity of vinorelbine combined with nedaplatin in treating advanced head and neck carcinoma. Methods Seventy-two patients with advanced head and neck carcinoma were treated with nedaplatin 80 mg/m^2 on days 1 and vinorelbine 25 mg/m^2 on day 1 and 8. The chemotherapy was repeated every 21 days. Each patient was trea-ted for at least 2 cycles. Results Complete response was observed in 3 cases, partial response in 37 cases, no response in 18 ca-ses and progression in 14 cases,the objective response rate was 55.6% （40/72） ,in which the primary cases was 72.2% （13/ 18 ） , relapse rate 50% （27/54）. Common toxicities were myelosuppression and gastrointestinal reactions, bone marrow suppression mainly reflected a reduction in white blood cells and platelcts,the incidence were 62.5% （45/72） and 48.6% （35/72） , Ⅲ-Ⅳ degree occurrence rate were only 8.3% , 11.1%, gastrointestinal reaction showed mild nausea and vomiting, there was no obvious liver and kidney damage. Conclusion Combination of vinorelbine and nedaplatin was better effective and well-tolerated in the treatment of advanced head and neck Carcinoma.
出处
《中华全科医学》
2013年第11期1713-1715,共3页
Chinese Journal of General Practice
